IRWD

Ironwood Pharmaceuticals, Inc.

Sağlık

NON-COMPLIANT — One or more ratios exceed the threshold; the company is not compliant with halal investment criteria.

$4.85

Price (1 Year)

$5.23 $3.04

Participation Finance Screening Ratios

Non-compliant debt / Total market cap %42.7 / %30
Non-compliant assets / Total market cap %3.7 / %30
Non-compliant revenue / Total income %1.1 / %5

Ratios are taken from an AAOIFI-based screening file; this does not constitute a religious ruling.

About the Company

Ironwood Pharmaceuticals, Inc., a biotechnology company, focuses on the development and commercialization of therapies for gastrointestinal (GI) and rare diseases in the United States and internationally. It sells linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation, as well as for pediatric patients suffering from functional constipation under the LINZESS and CONSTELLA names.

Website

Analysis (Turkish): IRWD Hissesi Caiz mi, Helal mi? Ironwood Pharmaceuticals, Inc. Katılım Analizi